CYTH - Cyclo Therapeutics, Inc. Stock Price, Fair Value and News

1.40USD+0.03 (+2.19%)Delayed

Market Summary

USD1.40+0.03

Delayed

2.19%

CYTH Stock Price

View Fullscreen

CYTH RSI Chart

CYTH Valuation

Market Cap

40.1M

Price/Earnings (Trailing)

-2.07

Price/Sales (Trailing)

18.7

EV/EBITDA

-1.91

Price/Free Cashflow

-2.23

CYTH Price/Sales (Trailing)

CYTH Profitability

EBT Margin

-905.20%

Return on Equity

-3.2K%

Return on Assets

-270.71%

Free Cashflow Yield

-44.93%

CYTH Fundamentals

CYTH Revenue

Revenue (TTM)

2.1M

Rev. Growth (Yr)

32.83%

Rev. Growth (Qtr)

-80.35%

CYTH Earnings

Earnings (TTM)

-19.4M

Earnings Growth (Yr)

13.26%

Earnings Growth (Qtr)

23.03%

Breaking Down CYTH Revenue

Last 7 days

-4.8%

Last 30 days

15.7%

Last 90 days

-20.4%

Trailing 12 Months

21.3%

How does CYTH drawdown profile look like?

CYTH Financial Health

Current Ratio

1.01

Debt/Equity

0.12

Debt/Cashflow

-253.11

CYTH Investor Care

Shares Dilution (1Y)

88.65%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	2.1M	0	0	0
2023	2.4M	2.2M	2.2M	2.1M
2022	1.4M	1.7M	1.7M	2.5M
2021	1.0M	1.2M	1.6M	1.5M
2020	1.1M	1.0M	835.0K	989.6K
2019	1.0M	957.9K	1.0M	1.0M
2018	1.1M	957.1K	940.4K	1.0M
2017	1.5M	1.6M	1.6M	1.2M
2016	1.1M	1.1M	1.1M	1.5M
2015	1.2M	1.4M	1.2M	950.5K
2014	1.7M	1.1M	1.4M	1.6M
2013	1.2M	1.7M	1.8M	1.7M
2012	1.2M	941.3K	867.4K	988.0K
2011	853.0K	912.6K	972.2K	1.0M
2010	0	0	0	793.4K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Cyclo Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 13, 2024	sieger markus	acquired	-	-	14,004	-
Feb 13, 2024	shanahan william s	acquired	-	-	8,466	-
Feb 13, 2024	wong vivien	acquired	-	-	6,330	-
Feb 13, 2024	strattan ce rick	acquired	-	-	6,963	-
Feb 13, 2024	conkling william	acquired	-	-	6,330	-
Feb 13, 2024	ostronic francis patrick	acquired	-	-	8,703	-
Feb 13, 2024	toig randall m.	acquired	-	-	7,516	-
Dec 27, 2023	cross shawn	acquired	-	-	72,606	-
Nov 28, 2023	conkling william	acquired	-	-	7,466	-
Nov 28, 2023	wong vivien	acquired	-	-	2,488	-

Which funds bought or sold CYTH recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	STATE STREET CORP	added	0.01	-7,898	54,947	-%
May 15, 2024	CITADEL ADVISORS LLC	added	0.18	-653	2,638	-%
May 15, 2024	CITADEL ADVISORS LLC	sold off	-100	-85,889	-	-%
May 15, 2024	Royal Bank of Canada	unchanged	-	-	1,000	-%
May 15, 2024	Tower Research Capital LLC (TRC)	added	12.11	-186	9,149	-%
May 15, 2024	Founders Fund V Management, LLC	unchanged	-	-96,142	668,184	61.12%
May 15, 2024	Steward Partners Investment Advisory, LLC	unchanged	-	-18.00	125	-%
May 15, 2024	EPIQ Capital Group, LLC	new	-	1,186,800	1,186,800	0.47%
May 15, 2024	Founders Fund VI Management, LLC	unchanged	-	-22,005	152,932	57.89%
May 15, 2024	BANK OF AMERICA CORP /DE/	added	92.86	16.00	38.00	-%

Are Funds Buying or Selling CYTH?

Are funds buying CYTH calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CYTH

No. of Funds

Unveiling Cyclo Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	armistice capital, llc	4.99%	1,501,625	SC 13G/A
Oct 24, 2023	rafael holdings, inc.	49%	12,780,543	SC 13D/A
Aug 07, 2023	rafael holdings, inc.	49%	12,157,214	SC 13D/A
May 11, 2023	rafael holdings, inc.	16.6%	2,514,970	SC 13D
Feb 14, 2023	armistice capital, llc	10.83%	1,030,000	SC 13G/A
Feb 10, 2023	armistice capital, llc	10.8%	10,300	SC 13G
Feb 12, 2021	hirschman orin	4.99%	209,383	SC 13G/A

Recent SEC filings of Cyclo Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
May 15, 2024	10-Q	Quarterly Report
Apr 29, 2024	10-K/A	Annual Report
Mar 18, 2024	10-K	Annual Report
Mar 04, 2024	8-K/A	Current Report
Feb 15, 2024	4	Insider Trading
Feb 15, 2024	4	Insider Trading
Feb 15, 2024	4	Insider Trading
Feb 15, 2024	4	Insider Trading
Feb 15, 2024	4	Insider Trading
Feb 15, 2024	4	Insider Trading

Peers (Alternatives to Cyclo Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	372.2B	85.6B	6.82%	-1.69%	9.67	4.35	5.68%	202.39%
MRK	332.3B	61.4B	4.65%	15.09%	144.1	5.41	6.11%	-82.30%
AMGN	167.7B	29.5B	18.35%	39.38%	44.55	5.68	12.76%	-52.47%
PFE	162.3B	57.8B	12.71%	-21.46%	129.52	2.81	76.51%	-86.81%
GILD	84.4B	27.4B	1.23%	-13.37%	174.21	3.07	1.51%	-91.32%
TEVA	18.4B	16.0B	23.52%	97.09%	-37.29	1.15	7.23%	71.10%
MID-CAP
ALKS	4.1B	1.7B	0.67%	-19.91%	9.41	2.37	54.01%	364.56%
PRGO	4.1B	4.6B	-0.70%	-10.77%	-528.11	0.89	-0.06%	94.55%
BHC	2.5B	9.0B	-21.94%	-21.03%	-5.45	0.28	10.01%	-27.45%
AMPH	2.1B	676.2M	8.56%	-0.82%	13.75	3.14	30.38%	66.04%
SMALL-CAP
TLRY	1.5B	743.2M	15.12%	-18.85%	-4.35	2.06	24.65%	80.36%
TXMD	25.8M	1.3M	18.52%	-47.17%	-3.49	19.84	-98.14%	-104.71%
ACRX	18.4M	89.6M	6.93%	25.60%	-1.29	0.19	287.27%	-129.41%
AGRX	2.5M	21.5M	2.70%	-90.89%	-0.32	0.12	66.16%	61.83%
ACOR	633.5K	115.7M	-50.00%	-97.38%	0	0.01	-2.22%	-352.48%

Cyclo Therapeutics, Inc. News

Latest updates

Cyclo Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-80.3%	202,450	1,030,109	495,477	414,402	152,411	1,174,082	452,167	649,842	194,904	360,301	450,490	373,618	358,133	381,912	72,319	209,594	325,734	227,363	285,914	273,095	220,826
Gross Profit	-	190,627	-	-	-	142,215	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Costs and Expenses	-9.5%	5,311,689	5,869,555	5,262,937	4,750,060	5,159,543	5,030,779	4,700,667	3,997,910	3,129,361	3,378,431	4,262,934	3,839,042	4,395,409	2,827,049	1,658,461	2,411,497	2,967,774	2,865,224	1,914,539	1,643,379	2,128,616
R&D Expenses	-31.3%	2,845,483	4,144,336	3,469,067	3,170,199	3,398,167	3,184,948	2,856,160	1,874,383	1,084,052	1,414,401	1,837,720	2,643,544	3,258,115	1,236,651	1,086,753	1,713,435	2,059,606	1,798,047	941,539	786,811	1,342,763
EBITDA Margin	5.6%	-9.04	-9.57	-8.66	-8.59	-7.27	-6.25	-7.99	-7.76	-9.43	-9.25	-9.05	-9.89	-	-	-	-	-	-	-	-	-
Interest Expenses	203.6%	756	249	4,341	3,736	1,730	-	-	-	-	3,525	-	-269	269	304	224	-	-	-	-	-	-
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	23.0%	-4,343,063	-5,642,409	-4,771,353	-4,636,455	-5,007,085	-4,980,427	-4,246,880	-3,451,990	-2,771,591	-2,792,386	-3,860,256	-3,597,398	-4,036,615	-2,679,610	-1,435,609	-2,192,392	-2,633,992	-2,635,015	-1,625,341	-1,368,011	-1,904,166
EBT Margin	5.6%	-9.05	-9.59	-8.67	-8.60	-7.28	-6.25	-8.00	-7.78	-9.44	-9.26	-9.06	-9.91	-	-	-	-	-	-	-	-	-
Net Income	23.0%	-4,343,000	-5,642,409	-4,771,353	-4,636,455	-5,007,085	-4,980,427	-4,246,880	-3,451,990	-2,771,591	-2,792,386	-3,860,256	-3,597,398	-4,036,615	-2,679,610	-1,435,609	-2,192,392	-2,633,992	-2,635,015	-1,625,341	-1,368,011	-1,904,166
Net Income Margin	5.6%	-9.05	-9.59	-8.67	-8.60	-7.28	-6.25	-8.00	-7.78	-9.44	-9.26	-9.06	-9.91	-	-	-	-	-	-	-	-	-
Free Cashflow	-43.9%	-6,184,553	-4,297,302	-4,041,199	-3,478,706	-4,370,239	-2,746,780	-3,191,955	-4,355,743	-4,834,849	-2,611,671	-3,026,842	-4,462,466	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-45.9%	7,164	13,248	5,597	4,643	4,097	4,215	8,488	11,842	15,924	19,521	11,097	14,243	18,141	14,188	4,132	2,262	2,286	4,113	5,862	7,591	1,905
Current Assets	-46.7%	6,570	12,318	5,512	4,548	3,993	4,159	8,422	11,777	15,850	19,436	10,992	14,121	18,021	14,050	3,972	2,088	2,097	3,958	5,690	7,403	1,688
Cash Equivalents	-67.6%	2,995	9,247	1,802	842	915	1,543	4,290	7,453	11,799	16,613	8,441	11,463	15,507	12,846	2,238	1,008	933	2,784	4,994	6,608	1,115
Inventory	-4.6%	243	254	210	237	244	254	271	261	221	227	254	269	258	238	421	217	229	243	384	398	413
Net PPE	-36.5%	24.00	38.00	41.00	46.00	50.00	55.00	60.00	55.00	59.00	60.00	64.00	68.00	50.00	54.00	57.00	60.00	61.00	14.00	16.00	17.00	18.00
Current Liabilities	-22.8%	6,536	8,468	6,622	6,096	4,500	3,481	2,875	2,102	2,876	3,831	3,420	3,035	3,707	3,673	4,560	4,057	3,952	3,141	2,337	2,705	2,637
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	71.00	98.00	-	-	-	-	-
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	87.00	61.00	-	-	-	-	-
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	71.00	98.00	-	-	-	-	-
Shareholder's Equity	-87.2%	610	4,757	-	-	-438	735	5,612	9,740	13,048	15,672	7,627	11,126	14,322	10,452	-	-	-	936	3,483	4,840	-
Retained Earnings	-5.2%	-88,199	-83,856	-78,214	-73,442	-68,806	-63,799	-58,819	-54,572	-51,120	-48,348	-45,556	-41,695	-38,098	-34,061	-31,382	-29,946	-27,754	-25,120	-22,485	-20,859	-19,491
Additional Paid-In Capital	0.2%	88,807	88,611	77,160	71,957	68,367	64,533	64,431	64,311	64,167	64,020	53,183	52,821	52,419	44,514	30,841	28,012	26,044	26,056	25,956	25,688	18,701
Shares Outstanding	0.2%	28,614	28,556	19,365	15,308	10,054	8,482	8,428	8,418	8,412	8,404	6,041	6,368	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	17,226	-	-	-	14,693	-	-	-	76,509	-	-	-	11,147	-	-	-	25,510	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-43.9%	-6,182	-4,294	-4,041	-3,478	-4,370	-2,746	-3,181	-4,355	-4,830	-2,611	-3,026	-4,439	-4,926	-3,061	-1,608	-2,061	-1,809	-2,220	-1,622	-1,521	-1,225
Share Based Compensation	-	173	-	127	41.00	92.00	72.00	89.00	87.00	107	64.00	181	-	50.00	-	-	-	-	-	-	-	7.00
Cashflow From Investing	100.0%	-	-2.42	-	-	-	-	18.00	11.00	9.00	10.00	7.00	-5.66	3.00	13.00	7.00	7.00	-41.01	10.00	9.00	9.00	8.00
Cashflow From Financing	-100.6%	-69.28	11,742	5,001	3,405	3,742	-	-	-	7.00	10,773	-1.78	402	7,584	13,657	2,831	-	-	-	-	7,005	115

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

CYTH Income Statement

2024-03-31

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
REVENUES
Product sales	$ 202,450	$ 152,411
Cost of products sold (exclusive of direct and indirect overhead and handling costs)	11,823	10,196
GROSS PROFIT	190,627	142,215
Costs and Expenses [Abstract]
Personnel	822,481	906,955
Research and development	2,845,483	3,398,167
Repairs and maintenance	2,363	1,252
Professional fees	630,388	482,835
Office and other	892,213	282,375
Board of Directors fees and costs	104,398	72,125
Depreciation	2,177	4,819
Freight and shipping	373	819
Loss on disposal of equipment	11,813	0
Total operating expenses	5,311,689	5,149,347
LOSS FROM OPERATIONS	(5,121,062)	(5,007,132)
Other Income, Nonoperating [Abstract]
Investment and other income, net	237,568	47
Investment and other income	540,431	0
Total other income (expense), net	777,999	47
LOSS BEFORE INCOME TAXES	(4,343,063)	(5,007,085)
PROVISION FOR INCOME TAXES	0	0
NET LOSS	$ (4,343,063)	$ (5,007,085)
BASIC AND DILUTED NET LOSS PER COMMON SHARE (in dollars per share)	$ (0.15)	$ (0.46)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING (in shares)	28,585,228	11,003,588

CYTH Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
CURRENT ASSETS
Cash and cash equivalents	$ 2,995,178	$ 9,246,592
Accounts receivable, net of allowances of $0 and $10,272, respectively	71,322	122,379
Inventory, net	242,530	254,352
Prepaid insurance and services	442,838	384,889
Prepaid clinical expenses	2,818,204	2,310,045
Total current assets	6,570,072	12,318,257
FURNITURE AND EQUIPMENT, NET	24,342	38,332
RIGHT-OF-USE LEASE ASSET, NET	569,476	890,949
TOTAL ASSETS	7,163,890	13,247,538
Current portion of lease liability	647,556	1,010,631
Accounts payable and accrued expenses	5,888,813	7,457,416
Total current liabilities	6,536,369	8,468,047
Lease liability, net of current portion	17,507	22,484
Total long-term liabilities	17,507	22,484
STOCKHOLDERS' EQUITY
Preferred stock, par value $.0001 per share, 5,000,000 shares authorized, 0 outstanding	0	0
Common stock, par value $.0001 per share, 250,000,000 shares authorized, 28,614,384 and 28,556,072 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	2,862	2,856
Additional paid-in capital	88,806,896	88,610,832
Accumulated deficit	(88,199,744)	(83,856,681)
Total stockholders' equity (deficit)	610,014	4,757,007
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)	$ 7,163,890	$ 13,247,538

About Cyclo Therapeutics, Inc.

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of neurodegenerative diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo that is in Phase IIb clinical trials for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.

CEO	Mr. N. Scott Fine
WEBSITE	https://cyclotherapeutics.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	9

Cyclo Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Cyclo Therapeutics, Inc.? What does CYTH stand for in stocks?

CYTH is the stock ticker symbol of Cyclo Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Cyclo Therapeutics, Inc. (CYTH)?

As of Fri May 17 2024, market cap of Cyclo Therapeutics, Inc. is 40.06 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CYTH stock?

You can check CYTH's fair value in chart for subscribers.

What is the fair value of CYTH stock?

You can check CYTH's fair value in chart for subscribers. The fair value of Cyclo Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Cyclo Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CYTH so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Cyclo Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether CYTH is over valued or under valued. Whether Cyclo Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Cyclo Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CYTH.

What is Cyclo Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, CYTH's PE ratio (Price to Earnings) is -2.07 and Price to Sales (PS) ratio is 18.7. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CYTH PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Cyclo Therapeutics, Inc.'s stock?

In the past 10 years, Cyclo Therapeutics, Inc. has provided 0.37 (multiply by 100 for percentage) rate of return.